Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Voyageur Pharmaceuticals Ltd VYYRF


Primary Symbol: V.VM

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Industry Can't Keep Up to Iodine Contrast Demand
View:
Post by biggdogg on Mar 01, 2024 9:33pm

Industry Can't Keep Up to Iodine Contrast Demand

Voyageur needs to execute its Earth to Bottle Iodine plan sooner than later!! The Industry cant keep up to demand!
From GE Healthcare:
https://www.gehealthcare.com/insights/article/preventing-future-global-shortages-of-iodinated-contrast-media-requires-industry-action
Unless manufacturers, providers, and the whole industry work together, the impact of contrast media shortages could be far greater and wider-ranging than anything we’ve seen with the 2022 supply shortage.
We expect global demand for iodinated contrast media — the diagnostic pharmaceuticals impacted by the Shanghai lockdown — to double in the next 10 years as the growing global prevalence of chronic disorders drives significant growth in CT procedures
.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities